Generate Biomedicines Inc's (NASDAQ:GENB) Lock-Up Period To End on August 26th

Key Points

• Generate Biomedicines’ lock-up period expires August 26, allowing company insiders and major shareholders to sell shares issued in the company’s 25 million-share, $400 million IPO.
• Analyst sentiment remains mixed but generally positive: six analysts rate the stock Buy, one rates it Hold and two rate it Sell, resulting in a “Moderate Buy” consensus and a $25.40 average price target.
• GENB recently traded at $16.08, with a market capitalization of about $2.06 billion. The company reported a quarterly loss of $0.52 per share, missing expectations by $0.04, alongside $6.31 million in revenue.

Generate Biomedicines' (NASDAQ:GENB - Get Free Report) lock-up period will expire on Wednesday, August 26th. Generate Biomedicines had issued 25,000,000 shares in its initial public offering on February 27th. The total size of the offering was $400,000,000 based on an initial share price of $16.00. After the expiration of Generate Biomedicines' lock-up period, company insiders and major shareholders will be able to sell their shares of the company.

Analyst Upgrades and Downgrades

GENB has been the topic of several research reports. HC Wainwright upped their price target on shares of Generate Biomedicines from $16.00 to $25.00 and gave the company a "buy" rating in a research note on Friday, May 8th. Morgan Stanley lifted their price objective on shares of Generate Biomedicines from $20.00 to $22.00 and gave the stock an "overweight" rating in a research note on Thursday, May 14th. Wall Street Zen downgraded shares of Generate Biomedicines from a "hold" rating to a "sell" rating in a report on Saturday, August 8th. Finally, Weiss Ratings began coverage on shares of Generate Biomedicines in a research report on Tuesday, August 11th. They set a "sell (d)" rating on the stock. Six investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus price target of $25.40.

Generate Biomedicines Price Performance

Shares of NASDAQ GENB opened at $16.08 on Wednesday. The firm has a fifty day moving average of $14.75. The firm has a market cap of $2.06 billion and a PE ratio of -10.11. Generate Biomedicines has a fifty-two week low of $11.00 and a fifty-two week high of $18.18.

Generate Biomedicines (NASDAQ:GENB - Get Free Report) last released its earnings results on Thursday, August 6th. The company reported ($0.52) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.48) by ($0.04). The firm had revenue of $6.31 million during the quarter. As a group, equities research analysts expect that Generate Biomedicines will post -2.29 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Generate Biomedicines

An institutional investor recently bought a new position in Generate Biomedicines stock. Bank of New York Mellon Corp purchased a new position in shares of Generate Biomedicines Inc (NASDAQ:GENB - Free Report) during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm purchased 57,326 shares of the company's stock, valued at approximately $967,000.

Generate Biomedicines Company Profile

Generate Biomedicines, Inc NASDAQ: GENB is a biotechnology company that applies machine learning and generative artificial intelligence to the design and discovery of novel therapeutics. The company develops computational platforms to create and optimize protein sequences and biological molecules with the goal of producing new medicines across a range of modalities. Its core activities center on algorithm-driven design, iterative experimental validation, and the translation of computational outputs into candidate therapeutic molecules.

Generate’s technology combines advanced computational models with high-throughput laboratory methods to accelerate discovery and improve the likelihood of producing viable drug candidates.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source